AstraZeneca among backers as Swiss cancer biotech raises $200 million

LONDON (Reuters) - An unlisted Swiss biotech company focused on developing "armed antibodies" to fight cancer has raised $200 million in a funding round backed by AstraZeneca and other private backers.